StockNews.AI
BNGO
StockNews.AI
4 hrs

Bionano to Participate in the H.C. Wainwright @ Home Event

1. Bionano's CEO will speak at the H.C. Wainwright event on October 15. 2. The event could enhance visibility and investor interest for BNGO. 3. Bionano provides genome analysis solutions for research and clinical applications. 4. The company emphasizes its optical genome mapping technology and software offerings. 5. Recorded sessions will be available for reviewing post-event, aiding stakeholder engagement.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in investor events usually boosts stock visibility and interest. Historical examples show positive stock movements following investor presentations or conferences.

How important is it?

The event can bring attention to Bionano's innovative technologies, potentially attracting new investors.

Why Short Term?

The immediate effect will be visible around the event date. Past events often prompt short-term trading activities.

Related Companies

CRISPACBILMN
October 07, 2025 08:00 ET  | Source: Bionano Genomics SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15th, 2025. Conference & Webcast Details Date:October 15, 2025Time:10:00 a.m. to 11:00 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register   A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 90 days. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com or www.bionanolaboratories.com. Bionano’s products are for research use only and not for use in diagnostic procedures. Contacts Company Contact: Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com Investor Relations: Kelly GuraGilmartin Group+1 (212) 229-6163IR@bionano.com

Related News